A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers

References

• KimJH, LeeJH, PaikSH, KimJH, ChiYH. Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res. 2012;35(7):1123–1126. doi:10.1007/s12272-012-0700-z22864732
   PubMed Web of Science ®Google Scholar
• Kanarb® (fimasartan) tablets [Investigator’s Brochure]. Seoul, Republic of Korea: Boryung Pharmaceutical Co. Ltd.; 2018.
   Google Scholar
• GhimJL, PaikSH, HasanuzzamanM, et al. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. J Clin Pharmacol. 2016;56(5):576–580. doi:10.1002/jcph.61826272450
   PubMed Web of Science ®Google Scholar
• KangWY, KimEH, SeongSJ, et al. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers. Int J Clin Pharmacol Ther. 2016;54(12):992–1003. doi:10.5414/CP20261527668695
   PubMed Web of Science ®Google Scholar
• KimTH, ShinS, BashirM, et al. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. Xenobiotica. 2014;44:913–925. doi:10.3109/00498254.2014.91535924786684
   PubMed Web of Science ®Google Scholar
• JeongES, KimYW, KimHJ, et al. Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3. Xenobiotica. 2015;45:10–18. doi:10.3109/00498254.2014.94281025034008
   PubMed Web of Science ®Google Scholar
• KimJW, YiS, KimTE, et al. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. J Clin Pharmacol. 2013;53:75–81. doi:10.1177/009127001143332823400746
   PubMed Web of Science ®Google Scholar
• Tradjenta® (linagliptin) tablets [prescribing information]. Binger Strasse, Germany: Boehringer Ingelheim Pharmaceuticals, Inc Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201280s005lbl.pdf. Accessed 1018, 2019.
   Google Scholar
• LangleyAK, SuffolettaTJ, JenningsHR. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy. 2007;27(8):1163–1180. doi:10.1592/phco.27.8.116317655515
   PubMed Web of Science ®Google Scholar
• CerielloA, InagakiN. Pharmacokinetic and pharmacodynamics evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populations. J Diabetes Investig. 2017;8(1):19–28.
   PubMed Web of Science ®Google Scholar
• HongKN, FusterV, RosensonRS, RosendorffC, BhattDL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. J Am Coll Cardiol. 2017;70(17):2171–2185. doi:10.1016/j.jacc.2017.09.00129050566
   PubMed Web of Science ®Google Scholar
• AliMK, BullardKM, SaaddineJB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–1624. doi:10.1056/NEJMsa121382923614587
   PubMed Web of Science ®Google Scholar
• CooperME, PerkovicV, GroopP-H, et al. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria. J Hypertens. 2019;37(6):1294–1300. doi:10.1097/HJH.000000000000203230540657
   PubMed Web of Science ®Google Scholar
• QiuDD, LiuJ, ShiJS, et al. Renoprotection provided by dipeptidyl peptidase-4 inhibitors in combination with angiotensin receptor blockers in patients with type 2 diabetic nephropathy. Chin Med J (Engl). 2018;131(22):2658–2665. doi:10.4103/0366-6999.24527730425192
   PubMed Web of Science ®Google Scholar
• YangYS, LimMH, LeeSO, et al. Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. Diabetes Obes Metab. 2018;20(7):1670–1677. doi:10.1111/dom.1328229546730
   PubMed Web of Science ®Google Scholar
• FriedrichC, MetzmannK, RoseP, MattheusM, PinnettiS, WoerleHJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35(1):A33–A42. doi:10.1016/j.clinthera.2012.12.00223328275
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. [webpage on the Internet] Clinical drug interaction studies – study design, data analysis, and clinical implications guidance for industry; 2017 Available from: https://www.fda.gov/media/82734/download. Accessed 34, 2020.
   Google Scholar
• YiS, KimTE, YoonSH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57(6):682–689. doi:10.1097/FJC.0b013e31821795d021394036
   PubMed Web of Science ®Google Scholar
• CaoCQ, XiangYF, ZhouZG. The clinical application of linagliptin in Asians. Ther Clin Risk Manag. 2015;11:1409–1419. doi:10.2147/TCRM.S6440226396526
   PubMed Web of Science ®Google Scholar
• ShinKH, KimTE, KimSE, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011;58:492–499. doi:10.1097/FJC.0b013e31822b909221765368
   PubMed Web of Science ®Google Scholar
• GuN, KimBH, LimKS, et al. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial. Clin Ther. 2012;34:1592–1600. doi:10.1016/j.clinthera.2012.06.00422727611
   PubMed Web of Science ®Google Scholar
• MudraDR, DesinoKE, DesaiPV. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. Curr Drug Metab. 2011;12(8):750–773. doi:10.2174/13892001179835699921568936
   PubMed Web of Science ®Google Scholar
• AkamineY, Yasui-FurukoriN, UnoT. Drug-drug interactions of P-gp substrates unrelated to CYP metabolism. Curr Drug Metab. 2019;20(2):124–129. doi:10.2174/138920021966618100314203630280663
   PubMed Web of Science ®Google Scholar